New Texas Lung Cancer Conference Planned with Busy Clinicians in Mind
Erin JungmeyerStephen Liu, MD, and Tina Cascone, MD, PhD, share what attendees can expect at the first ever Texas Lung Cancer Conference, an upcoming two-day CME meeting endorsed by the IASLC. Read more
ILCN Editor Dr. Corey J. Langer Reflects on the ‘Fantastic Voyage’ From Nihilism to Hope in Thoracic Oncology
Nick IppolitoIn addressing fellow TTLC 23 faculty, Dr. Langer recounted the perils and pitfalls, promises and poetry he has experienced in his 35 years in the field. Read more
Specialists Debate the Merits of Lorlatinib as a Universal First-Line Treatment for ALK+ Patients
Nick IppolitoDr. Lyudmila Bazhenova argues the drug’s superior PFS makes it the best first choice; however Dr. Justin Gainor says toxicity data show it may not be right for all patients. Read more
Study Explores First-Line Osimertinib for NSCLC Patients with Uncommon EGFR Mutations
Erin JungmeyerDuring TTLC 23, Johns Hopkins’ Tia Cheunkarndee presented data that highlight the vast heterogeneity of mutations—and their variable response to treatment. Read more
TTLC Keynote Speaker Explores Progress, Potential Breakthroughs of SCLC Therapies
Nick IppolitoDuring the Targeted Therapies of Lung Cancer meeting, MD Anderson’s Dr. Lauren Byers celebrated recent advances and highlighted areas in need of further research. Read more
Experts Debate TKI Use After Disease Progression for Patients with EGFR Mutations
Nick IppolitoDuring TTLC 23, Drs. Balazs Halmos and Mark Socinski presented the evidence for and against continued tyrosine kinase inhibitors use with chemotherapy for EGFR-positive patients with disease progression. Read more
Revisit all your favorite moments from #TTLC23 in our photo gallery. Read more
Conference chairs Drs. Paul Bunn, Charu Aggarwal, Lecia Sequist, and Joel Neal discuss what makes this meeting unique and share program highlights in a recent Q&A with ILCN. Read more
IASLC is now accepting abstract submissions for WCLC 2023 and nominations for committee membership and leadership. Read more
Increasing Evidence Demonstrates the Usefulness of ctDNA
Christian Rolfo, MD, PhD, MBA, Drhc+more
LALCA participants recap how the field of liquid biopsy continues to grow—from new biomarkers to new frontiers in early cancer detection. Read more